ClinicalTrials.gg
RecruitingNCT06017258Updated Oct 6, 2026

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

A Phase 1 interventional study of CD371-specific/YSNVz/I-18 CAR T cells in Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Acute Myeloid Leukemia, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.
Updated Oct 6, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Leukemia, Myeloid, Acute by Memorial Sloan Kettering Cancer Center — 9 open to participants now, 12 under way, none of them phase 3. Leukemia, Myeloid, Acute · Memorial Sloan Kettering Cancer Center.

Planned enrollment
24th of 32
15 · median 31
Started
2023
with 2 others
Phase 1
14 of 49
4 open now
Primary completion
2027-12
later than 4 of 11 live
Registered
42nd of 49
by date

Among the 49 studies in Leukemia, Myeloid, Acute by Memorial Sloan Kettering Cancer Center, this one is the 24th largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2023, is one of 14 in phase 1, reaches primary completion later than 4 of the 11 other live ones, and was the 42nd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

9 of the 49 studies in Leukemia, Myeloid, Acute by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Leukemia, Myeloid, Acute by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.

03

Conditions studied

  • Refractory Acute Myeloid Leukemia
  • Relapsed Acute Myeloid Leukemia
  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory

Keywords

  • Refractory Acute Myeloid Leukemia
  • Relapsed Acute Myeloid Leukemia
  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • ArmoRed
  • CLEAR-AML
  • CLEc12a
  • CD371
  • Memorial Sloan Kettering Cancer Center
  • 23-016
04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject Inclusion: Collection of T cells (Part A)

  • History of CD371+ AML

    • Any disease status is eligible for collection
    • Expression of CD371 at any level on AML blasts (any method of detection including IHC and/or flow cytometry)
  • Age/Weight

    • Pediatrics: ≥ 1 year and ≥ 10kg for collection for dose levels, 1, 2, and -1
    • ≥ 12 years and ≥ 40 kg for collection for dose level 1A.
    • Adults: no limit on age/weight for collection for dose levels 1, 2, and -1.
    • ≥ 40 kg for collection for dose level 1A.
  • Patients with history of allo-HCT are eligible for collection if:

    • ≥ 100 days post-transplant however, as noted in Section 6.1.2, patients must be ≥180 days post-transplant to be eligible for treatment
    • no evidence of active
    • off any agents for 30 days prior to collection (physiologic dose of is acceptable)

Subject Inclusion: Treatment with CD371-specific/YSNVz/IL-18 CAR T cells (Part B)

  • CD371+ AML (meeting criteria defined below) for primary refractory AML, late first relapse, and/or advanced disease:

    o Primary refractory AML: Patients are eligible from disease perspective in the event of failure to achieve a CR, CRh or CRi after one or more of the following regimens:

  • Two or more courses of standard intensive induction chemotherapy (e.g., cytarabine and daunorubicin given as "7+3," MEC, HiDAC, FLAG+idarubicin, etc.);
  • Two or more cycles of venetoclax in combination with one of the following (azacitidine OR decitabine OR low-dose cytarabine), with or without other agents;
  • Six or more cycles of azacitidine monotherapy OR four or more courses of decitabine monotherapy

    • Early first relapse: Patients are eligible from disease perspective in the event of first morphologic relapse or new extramedullary disease less than 12 months after previously having achieved CR, CRh, or CRi following AML-directed therapy
    • Late first relapse: Patients with first morphologic relapse or new extramedullary disease ≥12 months after previously having achieved CR, CRh, or CRi following AML-directed therapy may respond to intensive re-induction using the initial induction regimen and not eligible from a disease perspective unless the treating investigator feels the patient is unlikely to benefit from repeating the initial induction regimen (for example, relapse occurring 12 months into CR on continuous azacitidine/venetoclax therapy), in which case the rationale for considering enrollment must be clearly documented and risks, benefits, and alternatives discussed with the patient.
    • Advanced disease: Patients are eligible from disease perspective in the event of relapsed AML refractory to reinduction therapy, relapse following alloHCT, or second or later relapse.
    • Disease eligibility considerations for all patients: Patients with relapsed or refractory AML with susceptible mutations for which there is an FDA approved therapy (for example, IDH1 mutation, ivosidenib; IDH2 mutation, enasidenib; FLT3-ITD/TKD, gilteritinib) are not eligible from a disease perspective unless they meet one or more of the below criteria:
  • Failure to achieve CR, CRh, or CRi following therapy with one or more targeted therapies for relapsed or refractory AML directed to the actionable mutation(s);
  • Intolerance of one or more targeted therapies for relapsed or refractory AML directed to the actionable mutation(s);
  • Treating investigator feels the patient would be unlikely to benefit from FDA-approved targeted therapy based on disease characteristics, in which case the rationale for considering enrollment must be clearly documented and risks, benefits, and alternatives discussed with the patient Age: any age is eligible for treatment if eligible for collection

    o The first 3 patients in the first dose cohort must be ≥ 16 years of age, while the first 2 patients in subsequent cohorts must be ≥ 16 years of age (see Section 10.4) . Nopatient enrolled to dose level 1A shall be \<12 years of age (and first 2 patients must be ≥ 16 years of age).

  • Adequate performance status:

    • Age ≥ 16 years: ≤ 1 or Karnosfsky ≥ 60
    • Age \< 16 years: Lansky ≥ 60
  • Patients with history of allo-HCT are eligible for treatment if:

    • ≥ 180 days post-transplant
    • no evidence of active GVHD
    • off any systemic immunosuppressive agents for 30 days prior to treatment (physiologic dose of corticosteroids is acceptable)
    • Treating physician considers the patient to be a candidate for second alloHCT
  • Identification of a suitable donor/source for alloHCT as determined by the treating physician.
  • Adequate organ function is required, defined as follows:

    • Hepatic: Serum total ≤ 1.5 mg/dL, unless benign congenital hyperbilirubinemia or unless thought to be disease related.
    • Hepatic: and AST \< 3 times the unless thought to be disease-related.
    • Renal: serum creatinine \< 2.0 mg/100 ml (> 18 years) or ≤ 2.5 x institutional upper limit of normal (ULN) for age
  • If serum creatinine is outside the normal range, then > 40 mL/min/1.73m2 (calculated or estimated) or (mL/min/1.73m2) > 40% of predicted normal for age.

Normal GFR by Age Age: 1 week / Mean GFR +/-SD (mL/min/1.73 m2): 40.6 + / - 14.8 Age: 2 - 8 weeks / Mean GFR +/-SD (mL/min/1.73 m2): 65.8 + / - 24.8 Age: > 8 weeks / Mean GFR +/-SD (mL/min/1.73 m2): 95.7 +/- 21.7 Age: 2 - 12 years / Mean GFR +/-SD (mL/min/1.73 m2): 133 +/- 27 Age: 13 - 21 years (males) / Mean GFR +/-SD (mL/min/1.73 m2): 140 +/- 30 Age: 13 - 21 years (females) / Mean GFR +/-SD (mL/min/1.73 m2): 126.0 + / - 22.0 Abbreviations: GFR, glomerular f filtration rate; SD, standard deviation

  • Greater than 2 years old: Normal GFR is 100 mL/min/1.73m2.
  • Infants: GFR must be corrected for body surface area.

    • Cardiac: ≥ 50% by MUGA or resting echocardiogram.
    • Pulmonary: Adequate pulmonary function as assessed by ≥ 92% oxygen saturation on room air by pulse oximetry

Exclusion criteria

Exclusion Criteria:

Subject Exclusion: Collection of T cells (Part A)

  • Pregnant or lactating women; women of childbearing age, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of while receiving study treatment and for at least 12 months after all treatment is finished
  • Sexually active males, unless they are willing to use a condom during intercourse while receiving study treatment and for at least 12 months after all treatment is finished
  • Radiographically-detected or symptomatic CNS disease or CNS 3 disease (i.e., presence of ≥ 5/ul WBC in CSF). Subjects with adequately treated CNS leukemia are eligible.
  • Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject
  • Impaired cardiac function ( \< 50%) as assessed by ECHO or MUGA scan
  • Patients with following cardiac conditions will be excluded:

    • (NYHA) stage III or IV congestive heart failure
    • Myocardial infarction ≤ 6 months prior to enrollment
    • History of ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration
  • Positive serologic test results for
  • Acute or chronic infection as assessed by serologic (HBVsAg) or PCR results, defined as HBVsAg+, HBVcAb+, HBV PCR+.
  • Acute or chronic infection as assessed by serologic (HCV ab) or PCR results, defined as HCV Ab+ with reflex to positive HCV PCR
  • Patient/parent/LAR unable to give /

Subject Exclusion: Treatment with CD371-specific/YSNVz/IL-18 CAR T cells (Part B)

  • Bridging chemotherapy occurring \< 1 week prior to administration of LDC

    o Exception: hydroxyurea can be continued up to 72 hours prior to leukapheresis or 24 hours prior to LDC

  • Pregnant or lactating women
  • Radiographically-detected or symptomatic CNS disease or CNS 3 disease (i.e., presence of ≥ 5/ul WBC in CSF). Subjects with adequately treated CNS leukemia are eligible.
  • Isolated extramedullary disease
  • Lack of a suitable donor/source for HSCT as determined by the treating physician.
  • Patients with prior alloHCT are allowed as long as alloHCT occurred ≥100 days prior to date of treatment with CD371-specific/YSNVz/IL-18 CAR T cells and as long as the patient is without ongoing requirement for systemic graft-versus-host therapy
  • Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject
  • Impaired cardiac function (LVEF \< 50%) as assessed by ECHO or MUGA scan.
  • Patients with following cardiac conditions will be excluded:

    • New York Heart Association (NYHA) stage III or IV congestive heart failure
    • Myocardial infarction ≤ 6 months prior to enrollment
    • History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration
  • Positive serologic test results for HIV.
  • Acute or chronic HBV infection as assessed by serologic (HBVsAg) or PCR results, defined as HBVsAg+, HBVcAb+, HBV PCR+.
  • Acute or chronic HCV infection as assessed by serologic (HCV ab) or PCR results, defined as HCV Ab+ with reflex to positive HCV PCR
  • Active second that requires systemic treatments, with the exception of malignancy treated with curative intent and without evidence of disease for > 2 years before screening
  • Patient/parent/LAR unable to give informed consent
  • Any other condition/issue which, in the opinion of the treating physician, would make the patient ineligible for the study; conditions that in the Principal Investigator's opinion might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Dose Level 1

    Participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

    Biological: CD371-specific/YSNVz/I-18 CAR T cells

  • Experimental
    Dose Level 2

    Participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

    Biological: CD371-specific/YSNVz/I-18 CAR T cells

  • Experimental
    Step-Down Dose

    Participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

    Biological: CD371-specific/YSNVz/I-18 CAR T cells

Interventions

  • BiologicalCD371-specific/YSNVz/I-18 CAR T cells

    Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of CAR T cells

    Determine the Maximum Tolerated Dose/MTD of CAR T cells in participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

    Time frame: up to 6 months

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Mark Geyer, MD · Contact646-608-3745
  • Memorial Sloan Kettering Monmouth (Limited protocol activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Mark Geyer, MD · Contact646-608-3745
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Mark Geyer, MD · Contact646-608-3745
  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)
    Commack, New York 11725, United States
    Recruiting
    • Mark Geyer, MD · Contact646-608-3745
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Mark Geyer, MD · Contact646-608-3745
  • Memorial Sloan Kettering Cancer Center (All protocol activites)
    New York, New York 10065, United States
    Recruiting
    • Mark Geyer, MD · Contact646-608-3745
  • Memorial Sloan Kettering Nassau (Limited Protocol Activites)
    Rockville Centre, New York 11553, United States
    Recruiting
    • Mark Geyer, MD · Contact646-608-3745
08

References and documents

Publications

  • Geyer MB, DeWolf S, Mi X, Weis K, Shaffer BC, Cadzin B, McAvoy D, Katsamakis Z, Lorenc R, Lewis AM, Gipson B, Cuibus MA, Girotra NN, Wu K, Smith N, Burns ER, Um JS, Yoo S, Masouleh BK, Galera P, Hosszu K, Chaudhari J, Wang X, Lin Q, Curran KJ, Park JH, Scheinberg DA, van den Brink MRM, Abdel-Wahab O, Brentjens RJ, Daniyan AF. CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia. Blood. 2025 Dec 25;146(26):3163-3174. doi: 10.1182/blood.2025029532. PubMed 40864984 ↗

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2027, 51 months after the start.

Of 307 non-industry phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 87. This study's planned 51 months is close to that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2023
First posted
Aug 30, 2023
StartActual
Sep 1, 2023
Primary completionEst.
Dec 17, 2027was Dec 2026
CompletionEst.
Dec 17, 2027was Dec 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 17, 2026→Dec 17, 2027
Oct 6, 2026
Study completion
Dec 17, 2026→Dec 17, 2027
Oct 6, 2026
Eligibility
4 inclusion criteria edited, 3 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedPediatrics: ≥ 1 year and ≥ 10kg for collection for dose levels, 1, 2, and -1
  • Added≥ 12 years and ≥ 40 kg for collection for dose level 1A.
  • EditedAdults: no limit on age/weight for collection for dose levels 1, 2, and -1.
  • Added≥ 40 kg for collection for dose level 1A.
  • Added≥ 100 days post-transplant however, as noted in Section 6.1.2, patients must be ≥180 days post-transplant to be eligible for treatment
  • Editedo The first 3 patients in the first dose cohort must be ≥ 16 years of age, while the first 2 patients in subsequent cohorts must be ≥ 16 years of age (see Section 10.4) . Nopatient enrolled to dose level 1A shall be <12 years of age (and first 2 patients must be ≥ 16 years of age).
  • Removed≥ 100 days post-transplant
  • Edited≥ 100180 days post-transplant
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Primary completion Dec 17, 2026→Dec 17, 2027
    Study completion Dec 17, 2026→Dec 17, 2027
    Eligibility 4 inclusion criteria edited, 3 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedPediatrics: ≥ 1 year and ≥ 10kg for collection for dose levels, 1, 2, and -1
    • Added≥ 12 years and ≥ 40 kg for collection for dose level 1A.
    • EditedAdults: no limit on age/weight for collection for dose levels 1, 2, and -1.
    • Added≥ 40 kg for collection for dose level 1A.
    • Added≥ 100 days post-transplant however, as noted in Section 6.1.2, patients must be ≥180 days post-transplant to be eligible for treatment
    • Editedo The first 3 patients in the first dose cohort must be ≥ 16 years of age, while the first 2 patients in subsequent cohorts must be ≥ 16 years of age (see Section 10.4) . Nopatient enrolled to dose level 1A shall be <12 years of age (and first 2 patients must be ≥ 16 years of age).
    • Removed≥ 100 days post-transplant
    • Edited≥ 100180 days post-transplant
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06017258
Responsible party
Sponsor
First posted
Aug 30, 2023
Start date
Sep 1, 2023
Primary completion
Dec 17, 2027 (estimated)
Completion
Dec 17, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Mark Geyer, MD
Contact
geyerm@mskcc.org
646-608-3745
Jae Park, MD
Contact
parkj6@mskcc.org
646-608-3743
Mark Geyer, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion